# Failure Analysis: Issue #2562 GWAS Drug Response Series (4 PRs)

## Issue Title
Add missing drug response terms for GWAS catalog

## PRs in Series
- PR #2563, #2564, #2565, #2569 (all closed)
- PR #2584 (eventually merged)

## Failure Mode
**Multiple duplicate PRs with WIP placeholders and inconsistent content**

## What Happened

1. Issue #2562 requested drug response terms for GWAS catalog
2. Agent created **4 PRs** that were all closed
3. Eventually PR #2584 was merged after reviewer feedback

### Timeline
| PR | Title | Terms | Status |
|----|-------|-------|--------|
| 2563 | [WIP] Add missing drug response terms | 0 (placeholder) | Closed |
| 2564 | Add 8 drug response terms | 8 terms | Closed |
| 2565 | Add drug response terms | 6 terms | Closed |
| 2569 | [WIP] Add missing drug response terms | Plan only | Closed |
| 2584 | Add 8 drug response terms | 8+ terms | **Merged** |

## Inconsistencies Across PRs

### PR #2564 proposed:
- response to apixaban, carboplatin, cytarabine, ethanol, gabapentin, paclitaxel, tenofovir alafenamide, tenofovir disoproxil fumarate

### PR #2565 proposed (different set):
- response to penicillin, amphetamine, zinc atom, psychotropic drug, anticoagulant, antioxidants

### Merged PR #2584:
- response to amphetamine, penicillin, tocilizumab, sunitinib, nintedanib, vandetanib, vemurafenib, mesalamine + 3 more

## Root Causes

1. **Inconsistent analysis** - Different sessions produced completely different drug lists
2. **WIP abandonment** - #2563 and #2569 never completed
3. **No verification** - Agent didn't verify which drugs actually needed terms
4. **Missing reviewer feedback loop** - Only merged PR incorporated reviewer comments

## Reviewer Feedback That Led to Success

From merged PR #2584:
> @copilot can you check again if there are any drugs that you have missed? In another pass you also found zinc, zonisamide, GLP-1 receptor agonist and DPP-4 inhibitor.

Agent responded and added more terms, leading to successful merge.

## Correct Approach

1. **Complete a thorough analysis once** - Don't produce different results each run
2. **Respond to reviewer feedback on existing PR** - Don't create new PRs
3. **Never abandon WIP PRs** - Complete or update them
4. **Verify results** - Cross-check which drugs actually need terms

## Lessons Learned

- Analysis methodology must be consistent across runs
- Reviewer feedback should trigger commits to existing PR, not new PRs
- The successful PR incorporated iterative feedback on the same branch
